APL-16-5

N/A

Report date: 2023/03/06 14:28:46
NME

Base Information

Drug NameAPL-16-5
Drug Alias NameAPL-16-5
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionPolymerase acidic protein degradersE3 ubiquitin/ISG15 ligase TRIM25 degraders
TargetsPolymerase acidic proteinE3 ubiquitin/ISG15 ligase TRIM25
Therapy Area/IndicationsInfluenza A virus infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInstitute Of Medical Biotechnology, Chinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Medical Biotechnology, Chinese Academy Of Medical Sciences
Inactive CompaniesN/A
Active IndicationsInfluenza A virus infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A